CFDE Data Portal | Search LOC112268208

	Label	Description
	LOC112268208 Gene (Entity type)	ENSG00000285095 - uncharacterized LOC112268208
	GSE252944 AKT inhibition 10 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE200982 PLAC8 knockout 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE113655 phenol 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE73573 KDM1B knockdown 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 6 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE222758 clofazimine U2OS 0 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE203522 dopamine SH-SY5Y 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS

LOC112268208

ENSG00000285095 - uncharacterized LOC112268208

GSE252944 AKT inhibition 10 v 15 human dn

A Gene Set from LINCS

GSE200982 PLAC8 knockout 0 v 2 human dn

A Gene Set from LINCS

GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn

A Gene Set from LINCS

GSE113655 phenol 1 v 2 human dn

A Gene Set from LINCS

GSE73573 KDM1B knockdown 1 v 0 human dn

A Gene Set from LINCS

GSE239844 crizotinib 6 v 0 human up

A Gene Set from LINCS

GSE222758 clofazimine U2OS 0 v 4 human up

A Gene Set from LINCS

GSE203522 dopamine SH-SY5Y 2 v 1 human up

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 3 v 7 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.